VBI Vaccines To Seek Approval For Sale And Investment Solicitation Process (SISP); Aims To Identify Purchasers For Assets Efficiently; Process To Be Administered By VBI With Assistance From Financial Advisor And Monitor, EY; Further Details To Be Disclosed In Due Course
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines (VBIV) is initiating a Sale and Investment Solicitation Process (SISP) to identify potential purchasers for its assets. The process will be managed by VBI with the assistance of financial advisor and monitor, EY. Further details will be disclosed later.
July 30, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
VBI Vaccines is initiating a Sale and Investment Solicitation Process (SISP) to efficiently identify purchasers for its assets. The process will be managed by VBI with assistance from EY. Further details will be disclosed in due course.
The initiation of a Sale and Investment Solicitation Process (SISP) by VBI Vaccines indicates a strategic move to potentially divest assets or attract investment. This could lead to a positive short-term impact on the stock price as investors may anticipate favorable outcomes from the process.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100